scholarly journals Challenges and Strategies for Access to Treatment of Hepatitis C in Latin America

2020 ◽  
Author(s):  
David Kershenobich ◽  
Nayelli Flores
Keyword(s):  
Latin America ◽  
Hepatitis C ◽  
Access To Treatment ◽  
Challenges And Strategies

scholarly journals Trends and projections of hepatitis C virus epidemiology in Latin America

2011 ◽  
Vol 31 ◽  
pp. 18-29 ◽  
Author(s):  
David Kershenobich ◽  
Homie A. Razavi ◽  
Juan Francisco Sánchez-Avila ◽  
Fernando Bessone ◽  
Henrique S. Coelho ◽  
...  
Keyword(s):  
Latin America ◽  
Hepatitis C Virus ◽  
Hepatitis C

scholarly journals The First Complete Genome Sequences of Hepatitis C Virus Subtype 2b from Latin America: Molecular Characterization and Phylogeographic Analysis

Proceedings ◽  
2020 ◽  
Vol 50 (1) ◽  
pp. 121
Author(s):  
Natália Spitz ◽  
José J. Barros ◽  
Kycia M. do Ó ◽  
Carlos E. Brandão-Mello ◽  
Natalia M. Araujo
Keyword(s):  
Latin America ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Latin American ◽  
Complete Genome ◽  
Direct Sequencing ◽  
Epidemiological Data ◽  
National Prevalence ◽  
Latin American Countries ◽  
Virus Subtype

The hepatitis C virus (HCV) has remarkable genetic diversity and exists as eight genotypes (1 to 8) with distinct geographic distributions. No complete genome sequence of HCV subtype 2b (HCV-2b) is available from Latin American countries, and the factors underlying its emergence and spread within the continent remain unknown. The present study was conducted to determine the first full-length genomic sequences of HCV-2b isolates from Latin America and reconstruct the spatial and temporal diversification of this subtype in Brazil. Nearly complete HCV-2b genomes isolated from two Brazilian patients were obtained by direct sequencing of long PCR fragments and analyzed together with reference sequences using the Bayesian coalescent and phylogeographic framework approaches. The two HCV-2b genomes were 9318 nucleotides (nt) in length (nt 37–9354). Interestingly, the long RT-PCR technique was able to detect the co-circulation of viral variants that contained an in-frame deletion of 2022 nt, encompassing E1, E2, and p7 proteins. Spatiotemporal reconstruction analyses suggest that HCV-2b had a single introduction in Brazil during the early 1980s, displaying an epidemic history characterized by a low and virtually constant population size to date. These results coincide with epidemiological data in Brazil and may explain the low national prevalence of this subtype.

scholarly journals 355. Barriers for Hepatitis C Elimination in HIV/HCV Coinfected Patients

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S187-S187
Author(s):  
Joe Espinoza ◽  
Karen J Vigil ◽  
Ben Barnett
Keyword(s):  
Hepatitis C ◽  
Open Access ◽  
People Living With Hiv ◽  
Access To Treatment ◽  
Active Intervention ◽  
Key Stakeholders ◽  
Wide Availability ◽  
Direct Acting ◽  
Treatment Use ◽  
Living With Hiv

Abstract Background Approximately 30% of people living with HIV are co-infected with Hepatitis C virus (HCV). HIV/HCV coinfected patients have faster progression to liver fibrosis, cirrhosis, and increased mortality, compared with monoinfected patients. Therefore, treatment in this population is a priority. The objective of this study was to develop an active program to reach HIV/HCV co-infected patients, with the goal to eliminate Hepatitis C in our local HIV clinic. Methods Beginning in December 2016, our clinic received State funds to support open access to treat HIV/HCV patients with direct-acting antivirals (DAA). From December 2016 to May 2018, the process was based on primarily on physician referrals to treat HIV/HCV patients at our clinic, without an active intervention, and 50 patients were treated. Our active intervention during the second part was based on the identification of all untreated HIV/HCV patients and contacting them directly, to link them to care. Results A total of 462 HIV/HCV co-infected patients were identified who qualified for the state-sponsored treatment program. From June 1, 2018 to July 31, 2018, only 7 patients were linked to care and started on DAA. The four main identified reasons for not getting DAA therapy were: no show up to the clinic appointments, poor adherence to their HIV antiretroviral treatment, use of drugs and not able to be reached (figure). Although drug use was listed as one of the main reasons for not receiving DAA therapy, it was not the defining reason for most patients. A majority of the patients had more than one obstacle preventing them from coming in to be treated. Conclusion Wide availability of DAA and open access to treatment is not enough to eliminate HIV/HCV co-infection. Innovative outreach processes with the active participation of key stakeholders are needed in order to eliminate this viral infection. Disclosures All authors: No reported disclosures.

Access to Treatment of Hepatitis C in Prison Inmates

2008 ◽  
Vol 54 (6) ◽  
pp. 1325-1330 ◽  
Author(s):  
Paul Strock ◽  
Joël Mossong ◽  
Karine Hawotte ◽  
Vic Arendt
Keyword(s):  
Hepatitis C ◽  
Prison Inmates ◽  
Access To Treatment

scholarly journals Hepatitis C in key populations in Latin America and the Caribbean: systematic review and meta-analysis

2015 ◽  
Vol 60 (7) ◽  
pp. 789-798 ◽  
Author(s):  
Monica Alonso ◽  
Annika Gutzman ◽  
Rafael Mazin ◽  
Carlos E. Pinzon ◽  
Ludovic Reveiz ◽  
...  
Keyword(s):  
Systematic Review ◽  
Latin America ◽  
Hepatitis C ◽  
Meta Analysis ◽  
Key Populations ◽  
The Caribbean

scholarly journals PIN5 THE PREVALENCE AND ECONOMIC BURDEN OF HEPATITIS C VIRUS INFECTION IN CANADA AND LATIN AMERICA: A SYSTEMATIC REVIEW

2011 ◽  
Vol 14 (3) ◽  
pp. A114
Author(s):  
S.M. Szabo ◽  
B.M. Donato ◽  
Y. Yuan ◽  
M. Bibby ◽  
R. Jimenez-Mendez ◽  
...  
Keyword(s):  
Systematic Review ◽  
Latin America ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Infection ◽  
Economic Burden ◽  
Hepatitis C Virus Infection
Sign in / Sign up

Export Citation Format

Share Document